Home › Funds › Tetragon Partners GP Ltd › AUTL

Tetragon Partners GP Ltd position in AUTL

AUTOLUS THERAPEUTICS LTD · Health Care

Tetragon Partners GP Ltd reported holding 9,500,000 shares of AUTL (AUTOLUS THERAPEUTICS LTD) in its Q2 2026 13F filing — a position valued at US$15.2M, representing 2.48% of its reported portfolio and ranking #3 among its reported holdings. Tetragon Partners GP Ltd has disclosed AUTL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)9.50M sh
Reported value held$15.20M
Portfolio Weight2.48%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Tetragon Partners GP Ltd's AUTL position evolved

Tetragon Partners GP Ltd first disclosed a stake in AUTL in Q3 2023 at 12,000,000 shares (US$28.0M). The position peaked in Q4 2023 at 8,000,000 shares, worth US$51.5M. Across 12 filings, Tetragon Partners GP Ltd increased the stake 4 time(s), trimmed it 2 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 9,500,000 shares valued at US$15.2M. Notable position changes include a 33% trim in Q4 2023 (shares were roughly flat over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 12.00M $27.96M New
Q4 2023 8.00M $51.52M Reduce
Q1 2024 7.53M $48.01M Reduce
Q2 2024 8.00M $27.84M Add
Q3 2024 8.00M $29.04M Hold
Q4 2024 8.25M $19.39M Add
Q1 2025 8.60M $13.33M Add
Q2 2025 9.50M $21.66M Add
Q3 2025 9.50M $15.48M Hold
Q4 2025 9.50M $18.91M Hold
Q1 2026 9.50M $13.11M Hold
Q2 2026 9.50M $15.20M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AUTL and 13F data

AUTL (AUTOLUS THERAPEUTICS LTD) is a Health Care company. 18 other funds we track also report a position in AUTL — the largest reported positions include MAK CAPITAL ONE LLC (US$53.8M), Syncona Portfolio Ltd (US$26.6M), ARMISTICE CAPITAL, LLC (US$24.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AUTL

All AUTL fund holders →

FAQ

How long has Tetragon Partners GP Ltd held AUTL?

Tetragon Partners GP Ltd has disclosed AUTL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Tetragon Partners GP Ltd's current position in AUTL?

As of Q2 2026, Tetragon Partners GP Ltd holds 9.50M shares of AUTL (AUTOLUS THERAPEUTICS LTD), valued at $15.20M, representing 2.48% of its reported portfolio and ranking #3.

Has Tetragon Partners GP Ltd been buying or selling AUTL?

In the latest 13F filing (Q2 2026), Tetragon Partners GP Ltd held unchanged its position in AUTL. The position peaked in Q4 2023 at 8.00M shares.

Which other funds hold AUTL?

Other major institutional holders of AUTL include MAK CAPITAL ONE LLC, Syncona Portfolio Ltd, ARMISTICE CAPITAL, LLC, among 18 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.